Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in dark agouti rat: Temporal, spatial, and cellular patterns

Journal of Comparative Neurology

Volumn 497, Issue 2, 2006, Pages 251-269

  Ádori, Csaba ^a   Andó, Rómeó D ^a   Kovács, Gábor G ^a   Bagdy, György ^a,b  

^a NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

3,4 Methylenedioxymethamphetamine (MDMA); GFAP; Hsp27; Hsp70; Hsp90; Tryptophan hydroxylase

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BIOLOGICAL MARKER; CHAPERONE; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; TRYPTOPHAN HYDROXYLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARTICLE; ASTROCYTE; AXONAL INJURY; BRAIN REGION; CELLULAR DISTRIBUTION; CINGULATE GYRUS; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MACROGLIA; MALE; NONHUMAN; OCCIPITAL CORTEX; PRIORITY JOURNAL; PUTAMEN; PYRIFORM CORTEX; RAT; RAT STRAIN; SEPTUM NUCLEUS; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM;

ANIMALS; AXONS; BLOTTING, WESTERN; BODY TEMPERATURE; BRAIN; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT-SHOCK PROTEINS; HSP72 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR CHAPERONES; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEOPLASM PROTEINS; NEURONS; RATS; SEROTONIN; SEROTONIN AGENTS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 33744732146     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.20994     Document Type: Article

References (65)

1. Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, Lasberas B. 1999. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 10:3675-3680.
2. Akbar MT, Wells DJ, Latchman DS, de Belleroche J. 2001. Heat shock protein 27 shows a distinctive widespread spatial and temporal pattern of induction in CNS glial and neuronal cells compared to heat shock protein 70 and caspase 3 following kainate administration. Brain Res Mol Brain Res 93:148-163.
3. Arrigo AP, Firdaus WJ, Mellier G, Moulin M, Paul C, Diaz-Iatoud C, Kretz-remy C. 2005. Cytotoxic effects induced by oxidative stress in cultured mammalian cells and protection provided by Hsp27 expression. Methods 35:126-138.
4. Balogh B, Molnar E, Jakus R, Quate L, Olverman HJ, Kelly PA, Kantor S, Bagdy G. 2004. Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. Psychopharmacology (Berl) 173:296-309.
5. Brown PL, Kiyatkin EA. 2004. Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci 20:51-58.
6. Cadet JL, Ladenhcim B, Baum I, Carlson E, Epstein C. 1994. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res 655:259-262.
7. Callahan BT, Cord BJ, Ricaurte GA. 2001. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40:113-121.
8. Chang L, Ernst T, Grob CS, Poland RE. 1999. Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. J Magn Reson Imaging 10:521-526.
9. Colado MI, Williams JL, Green AR. 1995. The hyperthermic and neurotoxic effects of 'ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281-1289.
10. Colado MI, O'Shea E, Granados R, Murray TK, Green AR. 1997. In vivo evidence of free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121:889-900.
11. Concannon CG, Gorman AM, Samali A. 2003. On the role of Hsp27 in regulating apoptosis. Apoptosis 8:61-70.
12. Cotton RG, McAdam W, Jennings I, Morgan FJ. 1988. A monoclonal antibody to aromatic amino acid hydroxylases. Identification of the epitope. Biochem J 255:193-196.
13. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. 1998. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79:129-168.
14. de la Torre R, Farre M. 2004. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508.
15. Eddleston M, Mucke L. 1993. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience 54:15-36.
16. Engel K, Knauf U, Gaestel M. 1991. Generation of antibodies against human hsp27 and murine hsp25 by immunization with a chimeric small heat shock protein. Biomed Biochim Acta 50:1065-1071.
17. Fukumura M, Cappon GD, Pu C, Broening HW, Vorhees CV. 1998. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res 806:1-7.
18. Garcia-Osta A, Del Rio J, Frechilla D. 2004. Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus. Brain Res Mol Brain Res 126:181-187.
19. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J. 2003. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27:819-827.
20. Green AR, Cross AJ, Goodwin GM. 1995. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Psychopharmacology (Berl) 119:247-260.
21. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. 2003. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508.
22. Gudelsky GA, Yamamoto BK. 2003. Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine. Methods Mol Med 79:55-73.
23. Haan EA, Jennings IG, Cuello AC, Nakata H, Fujisawa H, Chow CW, Kushinsky R, Brittingham J, Cotton RG. 1987. Identification of serotonergic neurons in human brain by a monoclonal antibody binding to all three aromatic amino acid hydroxylases. Brain Res 426:19-27.
24. Hartl FU. 1996. Molecular chaperones in cellular protein folding. Nature 381:571-579.
25. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. 2004. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 173:383-390.
26. Jakab RL, Bowyer JF. 2002. Parvalbumin neuron circuits and microglia in three dopamine-poor cortical regions remain sensitive to amphetamine exposure in the absence of hyperthermia, seizure and stroke. Brain Res 958:52-69.
27. Jcnsen KF, Olin J, Haykal-Coates N, O'Callaghan J, Miller DB, de Olmos JS. 1993. Mapping toxicant-induced nervous system damage with a cupric silver stain: a quantitative analysis of neural degeneration induced by 3,4-methylenedioxymethamphetamine. NIDA Res Monogr 136:133-149; discussion 150-134.
28. Kalo K, Katoh-Semba R, Takeuchi IK, Ito H, Kamei K. 1999. Responses of heat shock proteins hsp27, alphaB-crystallin, and hsp70 in rat brain after kainic acid-induced seizure activity. J Neurochem 73:229-236.
29. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ. 2002. Functional consequences of perinatal exposing to 3,4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137:963-970.
30. Kloppel S, Kovacs GG, Voigtlander T, Wanschitz J, Flicker H, Hainfellner JA, Guentchev M, Budka H. 2001. Serotonergic nuclei of the raphe are not affected in human ageing. Neuroreport 12:669-671.
31. Kovacs GG, Kloppel S, Fischer I, Dorner S, Lindeck-Pozza E, Birner P, Botefur IC, Pilz P, Volk B, Budka H. 2003. Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 14:73-76.
32. Krueger-Naug AM, Hopkins DA, Armstrong JN, Plumier JC, Currie RW. 2000. Hyperthermic induction of the 27-kDa heat shock protein (Hsp27) in neuroglia and neurons of the rat central nervous system. J Comp Neurol 428:495-510.
33. Krueger-Naug AM, Plumier JC, Hopkins DA, Currie RW. 2002. Hsp27 in the nervous system: expression in pathophysiology and in the aging brain. Prog Mol Subcell Biol 28:235-251.
34. Kurucz I, Tombor B, Prechl J, Erdo F, Hegedus E, Nagy Z, Vitai M, Koranyi L, Laszlo L. 1999. Ultrastructural localization of Hsp-72 examined with a new polyclonal antibody raised against the truncated variable domain of the heat shock protein. Cell Stress Chaperones 4:139-152.
35. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
36. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F. 1999. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawdey and Dark Agouti rats. Pharmacol Biochem Behav 64:29-34.
37. Median AO, O'Shea E, Elliott JM, Colado MI, Green AR. 2001. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA: ecstasy) to rats results in a long-term defect in thermoregulation. Psychopharmacology (Berl) 155:413-418.
38. Miller EK, Raese JD, Morrison-Bogorad M. 1991. Expression of beat shock protein 70 and heat shock cognate 70 messenger RNAs in rat cortex and cerebellum after heat shock or amphetamine treatment. J Neurochem 56:2060-2071.
39. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA. 1990. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci 600:649-661; discussion 661-644.
40. Monks TJ, Jones DC, Bai F, Lau SS. 2004. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-136.
41. O'Callaghan JP, Miller DB. 1993. Quantification of reactive gliosis as an approach to neurotoxicity assessment. NIDA Res Monogr 136:188-212.
42. O'Callaghan JP, Miller DB. 1994. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
43. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. 1998. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37:919-926.
44. Ohtsuka K, Suzuki T. 2000. Roles of molecular chaperones in the nervous system. Brain Res Bull 53:141-146.
45. Omar R, Pappolla M. 1993. Oxygen free radicals as inducers of heat shock protein synthesis in cultured human neuroblastoma cells: relevance to neurodegenerative disease. Eur Arch Psychiatry Clin Neurosci 242:262-267.
46. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, Colado MI. 2004. 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89:1445-1453.
47. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. San Diego: Academic Press.
48. Pedersen NP, Blessing WW. 2O01. Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 21:8648-8654.
49. Plumier JC, David JC, Robertson HA, Currie RW. 1997. Cortical application of potassium chloride induces the low-molecular weight heat shock protein (Hsp27) in astrocytes. J Cereb Blood Flow Metab 17:781-790.
50. Poblete JC, Azmitia EC. 1995. Activation of glycogen phosphorylase by serotonin and 3,4-methylenedioxymethamphetamine in astroglial-rich primary cultures: involvement of tile 5-HT2A receptor. Brain Res 680:9-15.
51. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E. 2003. Different glial response to methamphetamine- and methylenedioxymethamphetamine- induced neurotoxicity. Naunyn Schmied Arch Pharmacol 367:490-499.
52. Pubill D, Verdaguer E, Sureda FX, Camins A, Pallas M, Camarasa J, Escubedo E. 2002. Carnosine prevents methamphetamine-induced gliosis but not dopamine terminal loss in rats. Eur J Pharmacol 448:165-168.
53. Quate L, McBean DE, Ritchie IM, Olverman HJ, Kelly PA. 2004. Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat. Psychopharmacology (Berl) 173:287-295.
54. Quraishi H, Brown IR. 1995. Expression of heat shock protein 90 (hsp90) in neural and nonneural tissues of the control and hyperthermic rabbit. Exp Cell Res 219:358-363.
55. Renkawek K, Bosman GJ, de Jong WW. 1994. Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. Acta Neuropathol (Berl) 87:511-519.
56. Riehl RM, Sullivan WP, Vroman BT, Bauer VJ, Pearson GR, Toft DO. 1985. Immunological evidence that the nonhormone binding component of avian steroid receptors exists in a wide range of tissues and species. Biochemistry 24:6586-6591.
57. Schmued LC. 2003. Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974:127-133.
58. Sprague JE, Nichols DE. 2005. Neurotoxicity of MDMA (ecstasy): beyond metabolism. Trends Pharmacol Sci 26:59-60; author reply 60-51.
59. Stone DM, Merchant KM, Hanson GR, Gibb JW. 1987. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677-1683.
60. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM. 2004. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367:349-354.
61. Vorhees CV, Morford LL, Inman SL, Reed TM, Schilling MA, Cappon GD, Moran MS, Nebert DW. 1999. Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine. Pharmacogenetics 9:171-181.
62. Wang X, Baumann MH, Xu H, Rothman RB. 2004. 3,4- Methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53:240-248.
63. Weissmann D, Belin MF, Aguera M, Meunier C, Maitre M, Cash CD, Ehret M, Mandel P, Pujol JF. 1987. Immunohistochemistry of tryptophan hydroxylase in the rat brain. Neuroscience 23:291-304.
64. Yang CY, Lin MT. 2002. Oxidative stress in rats with heatstroke-induced cerebral ischemia. Stroke 33:790-794.
65. Yu X, Imam SZ, Newport GD, Slikker W Jr, Ali SF. 1999. Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice. Brain Res 823:213-216.